Barclays raised the firm’s price target on Labcorp (LH) to $290 from $275 and keeps an Equal Weight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp partners with Roche to advance digital pathology capabilities
- Labcorp Holdings to Release Q3 2025 Financial Results
- Labcorp Holdings to Join Morgan Stanley Healthcare Conference
- Labcorp price target raised to $311 from $302 at Baird
- Labcorp launches first FDA-cleared blood test for Alzheimer’s disease